As discussed above, patients with HER2+ T1N0 breast cancer have excellent outcomes with adjuvant therapy as per the APT regimen [16], but some patients with cT1 cN0 tumours may have pathologic node-positive disease [17]. This evidence concerns the gene ERBB2 and neoplasm.